RS
Richard Sproll Portfolio
Invests via Tejara Capital Ltd. | Managed by Richard Sproll
Invests via Tejara Capital Ltd.
Managed by Richard Sproll
Automatically Tracked
Richard Sproll Profile
With a robust career rooted in healthcare technology, Richard Sproll has emerged as a distinguished leader in digital health innovation. His experience spans over two decades of driving growth and operational excellence within startups and established enterprises alike. Recognized for his acumen in product development, he plays a pivotal role in shaping strategies that enhance patient care through technological advancements. Sproll's commitment to transforming health systems makes him an influential figure at the intersection of entrepreneurship and investment, drawing interest from investors looking to capitalize on disruptive trends in the industry.
With a robust career rooted in healthcare technology, Richard Sproll has emerged as a distinguished leader in digital health innovation. His experience spans over two decades of driving growth and operational excellence within startups and established enterprises alike. Recognized for his acumen in product development, he plays a pivotal role in shaping strategies that enhance patient care through technological advancements. Sproll's commitment to transforming health systems makes him an influential figure at the intersection of entrepreneurship and investment, drawing interest from investors looking to capitalize on disruptive trends in the industry.
Investment Philosophy & Strategy
In the rapidly evolving landscape of healthcare technology, Richard Sproll’s insights guide his investment approach toward impactful innovations. His strategic foresight enables the identification of high-potential ventures that not only enhance operational efficiencies but also improve patient outcomes. With a blend of entrepreneurial experience and an in-depth understanding of market dynamics, he prioritizes investments in startups poised for disruption. This focus on technological advancement underlines a commitment to shaping a healthier future through scalable solutions, making him a vital ally for entrepreneurs seeking to transform their visions into reality.
In the rapidly evolving landscape of healthcare technology, Richard Sproll’s insights guide his investment approach toward impactful innovations. His strategic foresight enables the identification of high-potential ventures that not only enhance operational efficiencies but also improve patient outcomes. With a blend of entrepreneurial experience and an in-depth understanding of market dynamics, he prioritizes investments in startups poised for disruption. This focus on technological advancement underlines a commitment to shaping a healthier future through scalable solutions, making him a vital ally for entrepreneurs seeking to transform their visions into reality.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
41.48%
Gain +2.23%
Monthly
0.88%
Yearly
11.11%
Drawdown
32.42%
$295.82M
Equity
Holdings
$295.82M
Investment
$253.55M
$21.87M
Profit +$6.38M
Realized
-$20.4M
Unrealized
$42.27M
Dividends
$24.49M
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
2.23%
Profit
$6.38M
Win %
54%
This Week
Compared To Last Week
Gain
2.2%
Profit
$6.38M
Win %
54%
This Month
Compared to last month
Gain
-3.13%
Profit
-$9.56M
Win %
54%
This Year
Compared to last year
Gain
23.41%
Profit
$56.17M
Win %
58%
ADBE Adobe Inc.
0%
$0 
AESI Atlas Energy Solutions Inc.
0%
$0 
ALIT Alight Inc.
0%
$0 
AMD Advanced Micro Devices, Inc.
0%
$0 
APPN Appian Corporation
0%
$0 
AR Antero Resources Corporation
0%
$0 
ARQT Arcutis Biotherapeutics Inc.
0%
$0 
BG Bunge Global S.A.
0%
$0 
BILL Bill Holdings Inc.
0%
$0 
BL BlackLine, Inc. Common Stock
0%
$0 
BORR Borr Drilling Ltd.
0%
$0 
CAG Conagra Brands Inc.
0%
$0 
CE Celanese Corporation
0%
$0 
CERT Certara, Inc.
0%
$0 
CLB Core Laboratories Inc.
0%
$0 
CMCSA Comcast Corp
0%
$0 
CPB The Campbell's Company
0%
$0 
CRDL Cardiol Therapeutics Inc.
0%
$0 
CRM Salesforce Inc
0%
$0 
DNOW Dnow Inc.
0%
$0 
DVN Devon Energy Corporation
0%
$0 
ENOV Enovis Corporation
0%
$0 
EPAM Epam Systems Inc.
0%
$0 
ESTA Establishment Labs Holdings Inc.
0%
$0 
ESTC Elastic N.V.
0%
$0 
EVH Evolent Health Inc.
0%
$0 
FIS Fidelity National Information Services, Inc.
0%
$0 
FOUR Shift4 Payments, Inc.
0%
$0 
GIS General Mills, Inc.
0%
$0 
GPN Global Payments Inc.
0%
$0 
GTLB GitLab Inc.
0%
$0 
HRTX Heron Therapeutics Inc.
0%
$0 
HUBS HubSpot, Inc.
0%
$0 
INTU Intuit Inc.
0%
$0 
LITE Lumentum Holdings Inc.
0%
$0 
LYB LyondellBasell Industries N.V.
0%
$0 
MOS Mosaic Company
0%
$0 
MREO Mereo BioPharma Group plc - ADR
0%
$0 
MRVI Maravai Lifesciences Holdings Inc.
0%
$0 
MRVL Marvell Technology, Inc.
0%
$0 
MU Micron Technology, Inc.
0%
$0 
NKE Nike, Inc. - Class B
0%
$0 
NOW ServiceNow, Inc.
0%
$0 
NTCXF Natcore Technology Inc.
0%
$0 
OFIX Orthofix Medical Inc.
0%
$0 
PTEN Patterson-UTI Energy Inc.
0%
$0 
QDEL QuidelOrtho Corporation
0%
$0 
SDGR Schrödinger, Inc.
0%
$0 
SLB Schlumberger Limited
0%
$0 
SPRY Ars Pharmaceuticals Inc
0%
$0 
SPT Sprout Social, Inc. Class A Common Stock
0%
$0 
STRL Sterling Infrastructure, Inc.
0%
$0 
TDW Tidewater Inc.
0%
$0 
TEAM Atlassian Corporation Class A
0%
$0 
TXMD TherapeuticsMD, Inc.
0%
$0 
VAL Valaris Limited
0%
$0 
WDAY Workday Inc.
0%
$0 
WK Workiva Inc.
0%
$0 
EWY iShares MSCI South Korea ETF
0%
$0 
DEC Diversified Energy Company PLC
0%
$0 
SDRL Seadrill Limited
0%
$0 
FISV Fiserv, Inc.
0%
$0 
EXE Expand Energy Corporation
0%
$0 
CNR Core Natural Resources, Inc.
0%
$0 
SNDK SanDisk Corporation
0%
$0 NE
NE
0%
$0 No Data
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 949 | Longs Won 481/949 50% | Profit Factor 1.1 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $4M |
| Average Win $514,507.33 | Best Trade (Sep 03) $21.76M | Sharpe Ratio -134.27 |
| Average Loss -$482,696.33 | Worst Trade (Mar 30) -$119.48M | Z-Score -0.77 (56.1%) |
| Commissions $0 | Avg. Trade Length 9m 5d | Expectancy $23,044.29 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | 14.28% | 25.65% | 36.14% | 46.09% | 55.66% | 64.93% | 73.97% | 82.81% | 91.48% |
| Consecutive Losing Trades | 613 | 551 | 490 | 429 | 368 | 306 | 245 | 184 | 123 | 61 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ADBE Adobe Inc. | 16,880 | $3.97M | $4.45M | - | $479,338.72 | 12.08% | 0.0 |
| AESI Atlas Energy Solutions Inc. | 231,200 | $3.84M | $3M | - | -$839,256 | -21.85% | 0.0 |
| ALIT Alight Inc. | 1.59M | $5.02M | $19.41M | - | $14.39M | 286.93% | 0.0 |
| AMD Advanced Micro Devices, Inc. | 5,000 | $2.9M | $2.48M | - | -$423,550 | -14.58% | 0.0 |
| APPN Appian Corporation | 22,200 | $535,242 | $842,048.22 | - | $306,806.22 | 57.32% | 0.0 |
| AR Antero Resources Corporation | 284,400 | $10.16M | $10.81M | - | $646,496 | 6.36% | 0.0 |
| ARQT Arcutis Biotherapeutics Inc. | 113,084 | $2.66M | $2.76M | - | $93,294.28 | 3.5% | 0.0 |
| BG Bunge Global S.A. | 9,100 | $971,243 | $1.1M | - | $125,489 | 12.92% | 0.0 |
| BILL Bill Holdings Inc. | 219,400 | $8.18M | $10.93M | - | $2.74M | 33.49% | 0.0 |
| BL BlackLine, Inc. Common Stock | 239,237 | $8.16M | $7.2M | - | -$961,367.42 | -11.77% | 0.0 |
| BORR Borr Drilling Ltd. | 1.06M | $3.35M | $4.38M | - | $1.03M | 30.63% | 0.0 |
| CAG Conagra Brands Inc. | 46,800 | $629,928 | $694,746 | - | $64,818 | 10.29% | 0.0 |
| CE Celanese Corporation | 63,400 | $2.92M | $2.85M | - | -$71,008 | -2.43% | 0.0 |
| CERT Certara, Inc. | 1.29M | $9.84M | $10.25M | - | $412,388.22 | 4.19% | 0.0 |
| CLB Core Laboratories Inc. | 31,097 | $339,579.24 | $375,651.76 | - | $36,072.52 | 10.62% | 0.0 |
| CMCSA Comcast Corp | 180,000 | $4.55M | $4.49M | - | -$58,318.75 | -1.28% | 0.0 |
| CNR Core Natural Resources, Inc. | 107,109 | $8M | $10.35M | - | $2.35M | 29.42% | 0.0 |
| CPB The Campbell's Company | 28,600 | $636,922 | $611,039 | - | -$25,883 | -4.06% | 0.0 |
| CRDL Cardiol Therapeutics Inc. | 5.11M | $5.88M | $10.11M | - | $4.23M | 71.95% | 0.0 |
| CRM Salesforce Inc | 9,400 | $1.47M | $2.44M | - | $969,328 | 65.82% | 0.0 |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Richard Sproll?
The largest contributions to the portfolio's profits come from the following stocks: Arcutis Biotherapeutics Inc - $15.06M, Core Natural Resources Inc - $14.14M, Cameco Corporation - $7.78M, Teva Pharmaceutical Industries Ltd. ADR - $7.41M, and Establishment Labs Holdings Inc - $6.38M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: EOG Resources, Inc - $104.84M, Nabors Industries Ltd - $6.74M, New Fortress Energy Inc - $5.41M, Borr Drilling Ltd - $4.46M, and Transocean Ltd - $3.51M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Richard Sproll's portfolio generate?
The portfolio generates substantial dividend income, with a total of $24.49M earned over time. The largest contributors to dividend income include EOG Resources, Inc - $14.64M, Diversified Energy Company PLC - $2.27M, Viatris Inc - $743,168.04, Golar LNG Ltd - $742,346.5, and Core Natural Resources Inc - $710,113.8. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Richard Sproll's monthly returns?
Richard Sproll's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Richard Sproll's strategy be considered aggressive or moderate?
Richard Sproll's strategy appears moderately aggressive. The portfolio shows a clear focus on growth, with noticeable volatility and risk exposure, although not to an extreme level. This type of strategy may appeal to users seeking higher returns while accepting meaningful fluctuations along the way.
Should beginners follow Richard Sproll's strategy?
Richard Sproll's strategy is probably not ideal for beginners. The combination of risk, volatility, or portfolio complexity may make it harder to follow and understand without prior experience. Users who are new to investing may find it challenging to replicate or tolerate the performance swings.
